CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
SAGE-718drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04476017
NCT04476017Phase 2Completed
CompareCT.gov

An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment

Supernus Pharmaceuticals, Inc.·interventional·Posted Jul 17, 2020·Updated Sep 15, 2025

In Brief

A Phase 2 clinical trial evaluating SAGE-718 for Parkinson Disease and Cognitive Dysfunction. Completed, enrolled 18 participants across 4 sites.

Detailed Summary

The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Cognitive Dysfunction
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 17, 2020
Enrollment StartJul 31, 2020
Primary CompletionMar 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.0 years ago

Interventions

SAGE-718drug

Oral tablets.